A Pharmacokinetic/Pharmacodynamic Evaluation of ABF656 in Subjects With Chronic Hepatitis B, e Ag+, Infection.
Phase of Trial: Phase I/II
Latest Information Update: 20 Apr 2016
At a glance
- Drugs Albinterferon alfa 2B (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Novartis
- 23 Nov 2012 Company 'GlaxoSmithKline' added as reported by ClinicalTrials.gov.
- 05 Oct 2010 The status of this trial is uncertain because development of albinterferon alfa 2B has been discontinued, as reported by a Novartis media release.
- 01 Sep 2009 New trial record